Pharmaceutical powerhouse Eli Lilly has recently provided some much-needed good news for individuals dealing with fatty liver disease. In mid-stage trials, its drug tirzepatide, sold under the names Zepbound and Mounjaro, has demonstrated potential as a treatment for metabolic dysfunction associated steatohepatitis (MASH), a serious liver disease that involves extreme fat accumulation and inflammation.
During its most recent earnings announcement, Eli Lilly noted promising results. Approximately 74% of patients receiving the highest dose of tirzepatide appeared to be free of MASH, and there was no worsening of liver scarring over a year. The drug’s ability to decrease liver scarring resulted as clinically significant across all dosage levels. Driven by these encouraging outcomes, Eli Lilly plans to move forward into phase three trials.
Tirzepatide operates by activating two naturally occurring hormones that slow the emptying of the stomach. This function aids individuals in feeling full for extended periods and reduces appetite by delaying hunger cues in the brain. The drug is administered under the skin once a week, with the 15 mg dose showing the most effective outcomes.
The strides made by tirzepatide offer it a competitive advantage, especially when compared to Novo’s GLP-1 medication semaglutide, across multiple indications. Eli Lilly also has further tirzepatide trial results to anticipate, including potential impacts on obese patients with obstructive sleep apnea, heart failure with preserved ejection fraction, weight loss in obesity, and cardiovascular outcomes. A head-to-head weight loss experiment with tirzepatide and semaglutide is also currently underway.
Analysts are optimistic about tirzepatide’s future potential, particularly in the treatment of MASH. Esteemed investment bank Leerink Partners anticipates that multiple medication combinations will become the standard for care in this metabolic disorder. The MASH study has 196 participants enrolled, with all three doses of tirzepatide accomplishing the primary goal of absence of MASH without any worsening of liver fibrosis. The side effects reported in the study mirrored those in other tirzepatide tests, including nausea, diarrhea, vomiting, and stomach pain.
This advancement signals a crucial leap forward in the battle against fatty liver disease. As we anticipate more information from upcoming trials and approvals, the fight against this condition continues with renewed hope. The trial results from tirzepatide provide a beacon of hope in what has traditionally been a difficult medical problem.
